FDA Alerts HCPs, Patients Not To Use Sterile Drug Products from Vital Rx, Dba Atlantic Pharmacy, Com

The U.S. Food and Drug Administration is alerting health care professionals and patients not to use drug products intended to be sterile that are produced and distributed nationwide by Vital Rx, dba Atlantic Pharmacy and Compounding, Pompano Beach, Florida, due to lack of sterility assurance.

Health care professionals and patients should immediately check their medical supplies, quarantine any drug products labeled as sterile from Atlantic Pharmacy, and not administer them to patients. Health care professionals should make alternative arrangements to obtain any medications they administer to patients from reliable sources that adhere to proper quality standards.

During FDA’s recent inspection of Atlantic Pharmacy, investigators observed insanitary conditions, including poor sterile production practices, which raise concerns about Atlantic Pharmacy’s ability to assure the sterility of the drug products it produces. Administration of a non-sterile product intended to be sterile may result in serious and potentially life threatening infections or death.

On July 31, 2017, FDA recommended that Atlantic Pharmacy cease sterile production until appropriate corrective actions are implemented, and recall all non-expired drug products intended to be sterile. The company has not yet initiated a recall. Therefore, FDA is alerting health care professionals and patients to dispose of and not use drug products intended to be sterile that were produced and distributed by Atlantic Pharmacy.

To date, FDA is not aware of any reports of adverse events associated with drug products produced by Atlantic Pharmacy. Patients who have received drug products produced by Atlantic Pharmacy and have concerns should contact their health care professional.

FDA encourages health care professionals and patients to report adverse reactions or quality problems experienced with the use of human drug products from Atlantic Pharmacy to FDA’s MedWatch Adverse Event Reporting program:

Complete and submit the report online at www.fda.gov/medwatch/report.htm; or

Download and complete the form, then submit it via fax at 1-800-FDA-0178.